Smithkline Beecham Corporation

Erbamont Inc.

Scidose, LLC

Eagle Pharmaceuticals, Inc.

Geneva Pharmaceuticals, Inc.

Haz Two, LLC

Seidose, LLC

Pharmacia Corporation

Julie a. Hutt

Nageswara R. Palepu

Brian K. Boyd

Prafulla Agrawala

Nageswara R Palepu

Gopadi M Venkatesh

Sarma Duddu

Julie A Hutt

Tomaz R Herzyk

John Michael Jushchyshyn

Manga R Gudipati

Brian K Boyd

Fulvestrant formulations suitable for intramuscular injection at concentration in excess of 40 mg/ml in the absence of castor oil and castor oil derivatives are disclosed.

Fulvestrant formulations

Pharmaceutical formulations comprising docetaxel or a pharmaceutically acceptable salt thereof, one or more solubilizers, &#x3b1;-lipoic acid, TPGS, one or more hydrotropes, and optionally one or more agents having a pKof about 3 to about 6. The pharmaceutical formulations are stable and substantially free of excipients that can cause severe side effects and maintains chemical stability during storage. The pharmaceutical formulations are ready to be combined with an infusion solution for administration to patients in need thereof. Methods of treating patients in need thereof comprise administering the pharmaceutical formulations combined with an infusion solution.

Docetaxel formulations with lipoic acid

A storage stable aqueous solution of amifostine at a pH of at least 10.0, in an amifostine concentration of about 50 to about 250 mg/l, which formulation is storage stable under refrigerated conditions.

Stable amifostine liquid concentrate

Formulations comprising docetaxel or a salt thereof in combination with &#x3b1;-lipoic acid and/or dihydrolipoic acid and/or salts thereof in narrow concentration ranges have improved stability as concentrate liquid formulations and permit longer times between dilution from higher concentrations through completion of infusions prepared therefrom allowing for lesser waste and more efficient use of personnel in infusion preparation.

Docetaxel formulations with lipoic acid and/or dihydrolipoic acid

A lyophilization process which comprises dissolving a material in one or more solvents for said material to form a solution; forcing said material at least partially out of solution by combining the solution and a non-solvent for the material, which non-solvent is miscible with the solvent or solvents used and wherein said non-solvent is volatilizable under freeze-drying conditions. In addition, for hydrophobic and/or lipophilic materials, the anti-solvent can be omitted, and the solution of the material in the solvent can be subjected directly to freeze drying. The lyophilizates can then be reconstituted with typical aqueous diluent in the case of hydrophilic materials. Hydrophobic and or lipophilic materials can be initially reconstituted with propylene glycol and/or polyethyleneglycol to form a high concentration solution therein and this is further diluted for use with a diluent of Intralipid, plasma, serum, or even whole blood.

Lyophilization process and products obtained thereby

An aqueous formulation of argatroban and of related compounds is disclosed along with a reconstitutable formulation, each of which is substantially, if not totally alcohol free. The formulations are also substantially free, if not totally free, of mono-, di-, and oligo-saccharides. An especially preferred embodiment is a ready-to-administer 1 mg/ml injectable dosage form having argatroban, lactobionic acid, and methionine.

Alcohol free formulation of argatroban

The present invention relates to the treatment and prevention of bone diseases in humans, including osteoporosis in postmenopausal women, Paget's Disease and hypercalcemia, by administration of a bisphosphonate in an inhalation form. The invention also relates to pharmaceutical inhalation compositions suitable for the treatment and prevention of bone diseases.

Inhalation administration of biophosphonates

This invention relates to (E)-&agr;-&lsqb;2-n-butyl-1-&lsqb;(4-carboxyphenyl)methyl&rsqb;-1H-imidazol-5-yl&rsqb;methylene-2-thiophenepropionic acid arginyl charge-neutralization-complex, a process for its production, compositions containing the compound and methods of using the compound to block angiotensin II receptors and to treat hypertension, congestive heart failure and renal failure.

Eprosartan arginyl charge-neutralization-complex and a process for its preparation and formulation

This invention relates to a method for the manufacture of Bite-dispersion tablets which disperse easily and quickly in the oral cavity, after a gentle bite, without the aid of water, and if necessary includes masking the bitter taste of medicaments. The process comprises preparing a dry granulation of one or more of medicaments blended with suitable excipients, flavors and a combination of a waxy material and phospholipid (BMI-60) or an intense sweetener derived from fruit flavonoids (Neohesperidine) for taste-masking and compressing into tablets which can be packaged in bottles or blisters using conventional equipment.

Process for manufacturing bite-dispersion tablets

The invention relates to (E)-&agr;-&lsqb;2-n-butyl-1-&lsqb;(4-carboxyphenyl)methyl&rsqb;-1-H-imidazol-5-yl&rsqb;methylene-2-thiopheneproprionic acid monomethanesulfonate dihydrate, a process for its production, compositions containing the compound and methods of using the compound to block angiotensin II receptors and to treat hypertension, congestive heart failure and renal failure.

Eprosartan dihydate and a process for its production and formulation

A process for preparing controlled release solid dosage forms of lithium carbonate by using a dissolution rate stabilizer and a hydrophobic waxy material.

Controlled release solid dosage forms of lithium carbonate

This invention relates to (E)-&agr;-&lsqb;2-n-butyl-1-&lsqb;(4-carboxyphenyl)methyl&rsqb;-1) H-imidazol-5-yl&rsqb;methylene-2-thiophenepropionic acid monomethanfesulfonate monohydrate, compositions containing the compound and methods of using the compound to block angiotensin II receptors and to treat hypertension, congestive heart failure and renal failure.

Growing community of inventors

Southampton, PA, United States of America

Nageswara R Palepu